(Q33375532)

English

Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Somnuek Sungkanuparph

5

object named as

Somnuek Sungkanuparph

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Weerawat Manosuthi

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Preecha Tantanathip

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Wisit Prasithisirikul

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sirirat Likanonsakul

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

14 October 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

14 October 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

21 June 2018

Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

21 June 2018

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

21 June 2018

Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

21 June 2018

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

21 June 2018

Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

21 June 2018

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Mitochondrial dysfunction: patient monitoring and toxicity management

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-8-136

21 January 2018

Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

31 October 2018

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

31 October 2018

Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

31 October 2018

Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter cohort study. The Italian Zidovudine Evaluation Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2577100

10 December 2018

Effect of tuberculosis therapy on nevirapine trough plasma concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/18851761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18851761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18851761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18851761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-8-136

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33375532&oldid=2195300777"